AI Drug Discovery for Pharma and Biotech

Drug discovery

2

drugs

With orphan designations

Overview

ACTH-dependent Cushing syndrome results from excessive adrenocorticotropic hormone (ACTH) production, primarily due to pituitary adenomas (Cushing’s disease, ~70-80% of cases) or ectopic ACTH-secreting tumors (e.g., neuroendocrine tumors) [1][6][19]. Chronic hypercortisolism drives multisystem morbidity, including metabolic, cardiovascular, and psychiatric complications. Diagnosis requires dynamic hormonal testing (e.g., dexamethasone suppression, CRH stimulation) and imaging, with inferior petrosal sinus sampling to distinguish pituitary from ectopic sources [7][13].

Population

  • Annual incidence: 0.2–5.0 per million; female-to-male ratio 3–9:1 [1][7][11].

  • Median age at diagnosis: 41 years; pituitary adenomas account for 63–80% of endogenous cases [4][15][19].

Burden

  • Mortality risk 3.5–5× higher than general population, primarily due to cardiovascular/thromboembolic events [5][11][19].

  • ≥42% develop infections; 60% have hypertension/diabetes; osteoporosis occurs in 50–80% [5][7][15].

  • Prolonged hypercortisolism (>18 months) correlates with irreversible comorbidities [11][16][19].

Therapies

  • First-line: Transsphenoidal adenoma resection (curative in ~70% of pituitary cases) [3][8][12].

  • Second-line: Medical therapy (pasireotide, osilodrostat, ketoconazole) or radiation (stereotactic radiosurgery) for persistent/recurrent disease [1][8][14].

  • Ectopic ACTH: Tumor resection (if localized) or bilateral adrenalectomy for refractory cases [3][8][12].

Categories: rare endocrine diseases, rare infertility disorders

Research Papers

838 drug discovery papers about ACTH-dependent Cushing syndrome, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

838 drug discovery papers about ACTH-dependent Cushing syndrome, with 3 first-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-09-22 | Conversion therapy followed by curative resection in a patient with ACTH-secreting pancreatic neuroendocrine tumor G3: a case report

Background Pancreatic neuroendocrine tumors (pNETs) with ectopic adrenocorticotropic hormone (ACTH) production are uncommon, highly aggressive, and carry a dismal prognosis. Early nonspecific symptoms often delay diagnosis, and treatment strategies remain controversial. For patients with locally advanced pNETs, conversion therapy has only rarely been reported and remains a sparingly applied strategy. Case presentation A 37-year-old woman presented with a six-month history of progressive swelling in both lower extremities and her face. Further workup confirmed ACTH-dependent Cushing syndrome. CT and MRI identified a 5.7 × 2.8 cm lesion in the pancreatic body/tail that invaded the left adrenal gland and splenic vessels, accompanied by retroperitoneal lymph node spread. Biopsy results indicated a G3 pNET. Given the borderline resectable status due to local advancement, she received conversion therapy comprising a long-acting somatostatin analogue followed by CapTem chemotherapy. After three months of neoadjuvant treatment, imaging showed modest primary tumor shrinkage and marked reduction of lymph node size, reflecting successful downstaging. Subsequently, she underwent distal pancreatectomy with splenectomy, left adrenalectomy, and lymph node dissection, achieving R0 resection. Final pathology confirmed a G3 pNET (Ki-67 30%–40%) with positive SSTR2 and ACTH immunostaining. Although the patient eventually experienced disease progression and succumbed to COVID-19 infection 37 months after initial diagnosis, this case illustrates that conversion therapy can render an initially borderline resectable high-grade pNET amenable to curative resection. Conclusion This report underscores the aggressive trajectory of ACTH-secreting pNET G3 and suggests the potential utility of conversion therapy. Further studies are needed to validate this approach.

Open article ↗



2026-09-03 | Metyrapone in the Management of Severe Hypercortisolism Secondary to Ectopic Cushing's Syndrome.

Ectopic Cushing's syndrome (ECS) is a rare but important cause of ACTH-dependent Cushing's syndrome. Metyrapone, a steroidogenesis inhibitor targeting 11-β hydroxylase, has shown effectiveness in controlling hypercortisolism. However, little is known about the practical aspects of its initiation, use, and effectiveness in ECS. We present three cases of severe hypercortisolism secondary to ECS managed with metyrapone and report our experience. Case 1: a 56-year-old male with high-grade neuroendocrine carcinoma. Case 2: a 67-year-old man with a history of stage IIB non-small cell lung cancer (NSCLC) with metastatic neuroendocrine carcinoma. Case 3: a 64-year-old man with metastatic prostate cancer. Biochemical control was achieved with rapid titration of low doses of daily metyrapone in all three cases. Based on our experience, we recommend an initial dose of 1000-1500 mg of metyrapone daily, in divided doses, with physiologic glucocorticoid replacement to mitigate the risk of adrenal insufficiency. Despite improvements in cortisol levels and stabilization of metabolic derangements, all three patients ultimately transitioned to comfort-focused care. Given the rarity, heterogeneity, and aggressiveness of this condition, rapid diagnosis and standardized pharmacologic approach are difficult to achieve. More data are needed to guide optimal therapy selection, dosing, and titration in ECS.

Open article ↗



2026-08-13 | Ectopic ACTH-dependent Cushing syndrome in 3 hospitalized patients: lessons learned from management with osilodrostat.

Severe Cushing syndrome (CS) is a rare diagnosis with high mortality, which limits the ability of endocrinologists to gain experience delivering care. Here we describe our experience treating 3 cases of ectopic ACTH-dependent CS presenting in a single year. The initial diagnosis of each case was made during hospitalization resulting from complications of CS, implicating severe disease and delayed diagnosis. Our experience suggests that rapid initiation and titration of osilodrostat effectively treats hypercortisolism and improves outcomes.

Open article ↗



2026-08-01 | P246 - ECE_3578 - Osilodrostat in a block-and-replace strategy for successful management of cycling Cushing’s syndrome—case series

Abstract Introduction Cyclic Cushing’s syndrome (cCS) represents a significant clinical challenge due to unpredictable fluctuations in cortisol secretion, leading to heterogenous presentations and false-negative biochemical results. Although previously considered rare, cCS is increasingly recognized in clinical practice. Management is particularly difficult, and block-and-replace therapy with osilodrostat may provide effective cortisol stabilization. We present two illustrative cases from our clinic, highlighting the diagnostic process and practical use of osilodrostat in a block-and-replace strategy among patients with cCS. Case presentations A 68-year-old man with a 5-year history of recurrent hospitalizations due to infections and metabolic instability evaluated for bilateral adrenal incidentalomas. The patient presented with cushingoid features, and biochemical tests confirmed ACTH-dependent CS. Despite extensive imaging, the source of ACTH excess could not be identified. Retrospective analysis of the patient's history revealed multiple peaks of hypercortisolemia (morning serum cortisol 34.43-43.5 ug/dl) separated by spontaneous remissions (morning serum cortisol 8.02-13.3 ug/dl), correlating with episodes of hypertension and hyperglycemia, followed by hypotension and hypoglycemia. He was treated with metyrapone, temporarily in a block-and-replace regimen, however, marked cortisol variability required frequent dose adjustments. Initiation of low-dose osilodrostat (1 mg) in a continuous block-and-replace regimen (with hydrocortisone 5-10 mg daily) resulted in sustained biochemical and clinical stabilization for 13 months. Osilodrostat was discontinued prior to planned BIPSS, with the patient maintained on hydrocortisone replacement. Currently, the patient remains in an eucortisolemic phase 11 months after osilodrostat discontinuation. A 45-year-old woman was admitted after referral by her gynecologist, presenting with numerous cushingoid features, worsening hypertension, and diabetes. Biochemical and imaging tests confirmed Cushing’s disease (CD), leading to transsphenoidal surgery. She remained on hydrocortisone for six years, with several unsuccessful discontinuation attempts. Ambulatory cortisol measurements suggested normocortisolemia (morning serum cortisol 12.7-15.3 ug/dl), but during admissions for planned discontinuation, they were unexpectedly low (morning serum cortisol 3.6-7.66 ug/dl). After eventual adrenal function recovery, she experienced fluctuating control of comorbidities. BIPSS performed during peak of hypercortisolemia confirmed recurrent CD, and pituitary radiotherapy was performed. Block-and-replace therapy with osilodrostat was initiated at 4 mg daily with hydrocortisone 5-10 mg. Optimal disease control enabled dose reductions, with the patient currently stable on 1 mg of osilodrostat and 5 mg of hydrocortisone. Conclusions These cases illustrate the complexity of diagnosing and managing cCS. In both patients, the block-and-replace therapy with osilodrostat was well tolerated, effectively stabilized cortisol concentrations and controlled comorbidities, demonstrating its clinical value and safety in real-life management of cCS.

Open article ↗



2026-08-01 | EP1814 - LBA_ECE_1433 - Multimodal management of silent corticotroph tumors with Crooke's cell features transforming into severe Cushing's disease—the ERCUSYN Kraków cohort

Abstract Background Silent corticotroph tumors (SCTs) are pituitary neuroendocrine tumors of corticotroph lineage characterized by T-PIT positivity without clinical or biochemical hypercortisolism at diagnosis. Transforming into overt ACTH-dependent Cushing's disease (CD) has been reported in approximately 4% of cases, representing a rare but clinically significant phenomenon. Methods We report three patients from the ERCUSYN Kraków cohort with initially silent corticotroph PitNETs with Crooke's cell features who subsequently developed overt CD during long-term follow-up. Results A 53-year-old woman underwent resection of a nonfunctioning pituitary macroadenoma measuring up to 40 mm. Histopathology demonstrated a densely granulated corticotroph tumor with scattered Crooke's cells (Ki-67 approximately 3%). Proton radiotherapy was subsequently performed. Six years later, rapid tumor progression involving the sella and left cavernous sinus was observed together with biochemical ACTH-dependent hypercortisolism (loss of circadian rhythm, late-night cortisol 19.3 µg/dL, urinary free cortisol 308-445 µg/24 h, ACTH 97.7 pg/mL), despite only mild clinical manifestations. The progression was accompanied by severe mass-effect symptoms, including visual field impairment, ptosis, and convergent strabismus. Combination therapy with pasireotide LAR and temozolomide was initiated. Temozolomide was discontinued after the first cycle due to bone marrow aplasia, while continued pasireotide therapy resulted in radiological stabilization and normalization of cortisol levels. An 80-year-old man underwent incomplete transsphenoidal resection of a 35 mm nonfunctioning macroadenoma (Knosp grade 2). Histopathology confirmed a corticotroph PitNET with Crooke's cell features, followed by adjuvant radiotherapy. Approximately nine years later, the patient developed clinically overt ACTH-dependent CS without significant radiological tumor progression. Initial treatment with pasireotide was insufficient. Due to severe hypercortisolism, osilodrostat was initiated directly in a block-and-replace regimen (up to 30 mg/d) with hydrocortisone supplementation, resulting in biochemical remission and clinical improvement. A 71-year-old woman underwent four transsphenoidal resections of a corticotroph macroadenoma within two years followed by radiotherapy. Five years later, marked tumor progression (Knosp grade 4) occurred with severe mass-effect symptoms including convergent strabismus and impaired ocular motility. Treatment with pasireotide and temozolomide was initiated; however, overt CD developed during therapy. Osilodrostat was introduced and administered for six months, achieving biochemical control of hypercortisolism. Subsequently, temozolomide therapy was continued, and after seven cycles the patient remains clinically stable with radiological tumor regression. Conclusions SCTs with Crooke's cell features may transform into severe CD many years after the initial diagnosis, sometimes even without marked radiological progression. These observations highlight the importance of long-term endocrine surveillance and often necessitate multimodal therapeutic strategies including surgery, radiotherapy, and targeted medical therapy.

Open article ↗



cell therapies
2026-06-12 | ACTH-dependent Cushing's syndrome in MEN1: When multiple tumors complicate the diagnosis.

ACTH-dependent Cushing's syndrome (CS) is a rare manifestation of multiple endocrine neoplasia type 1 (MEN1). Identifying the ACTH source is challenging in MEN1 due to the frequent coexistence of multiple synchronous neuroendocrine tumors (NETs) in these patients. We describe the diagnostic dilemma in a 51-year-old male with MEN1 and severe ACTH-dependent CS. To analyze the specific diagnostic pitfalls in this population, we conducted a systematic literature review focusing exclusively on documented cases of ectopic Cushing syndrome (ECS) in MEN1 patients. The patient presented severe CS, with urinary free cortisol (UFC) at 3,188μg/24h (exceeding 25 times the upper limit of normal). Rapid biochemical control was achieved within 10 days using a high-dose (60mg/day) osilodrostat "block-and-replace" regimen. Imaging identified 3 potential sources: a 7×8mm pituitary microadenoma, a small pancreatic NET, and a large thymic NET (48×62×67mm). Despite a desmopressin stimulation test falsely suggesting a pituitary source (+118% ACTH increase), clinical severity and imaging indicated total thymectomy. Pathology confirmed a typical carcinoid tumor with ACTH expression. Postoperatively, the patient achieved complete remission. Our review of ectopic Cushing's syndrome (ECS) in MEN1 identified a total of 18 cases to date. Thymic NETs were the most frequent source (61%), followed by pancreatic NETs (28%). Notably, ectopic secretion of corticotropin-releasing hormone (CRH) was identified in 4 cases (22%), constituting a major diagnostic pitfall that led to unnecessary transsphenoidal surgery in 3 cases. ACTH-dependent CS in MEN1 is a diagnostic "perfect storm", where pituitary incidentalomas frequently mislead clinicians. Based on our review, ectopic CRH or ACTH secretion from thoracic or abdominal NETs must be systematically considered. We advocate a strategy prioritizing resection of the most suspicious lesion identified on imaging, thereby avoiding unnecessary transsphenoidal surgery.

Open article ↗



2023-10-01 | THU014 Post-surgical Remission After Resection Of Solitary Mediastinal Lymph Node In A Metastatic Occult Ectopic ACTH Syndrome Patient

Abstract Disclosure: I.P. de Magalhães: None. C.P. Oliveira: None. L.P. Lins: None. N.X. Andrade: None. M.S. Lima: None. S.A. Siqueira: None. J.S. Fonini: None. E.C. Assis Filho: None. A.W. Mariani: None. M.C. Machado: None. BACKGROUND: The prevalence of occult cases has been increasing in the most recent series of Ectopic ACTH syndrome (EAS) maybe due to the small size of pulmonary neuroendocrine tumors. We present an atypical and very rare case of EAS with initial presentation of a single metastatic mediastinal lymph node that evolved with remission after your resection with no defined primary tumor. CASE REPORT: A 15-year-old female patient presented a clinical feature of Cushing’s syndrome (CS) with a 1-year evolution. Hormonal evaluation confirmed ACTH-dependent CS: urinary free cortisol of 819 µg/24h (3-43), late night salivary cortisol of 409 ng/dL (<274) and ACTH of 105 pg/mL (<63.3). Noninvasive methods for differential diagnosis of ACTH-dependent CS did not clarify the etiology (conflicting results): pituitary MRI negative, suppression of 59.6% of cortisol after high dose dexamethasone suppression test, positive response of ACTH and cortisol at desmopressin test, suppression of 81% of ACTH at acute octreotide SC test, negative serum tumor markers (gastrin, calcitonin, CEA, CA125, alpha-fetoprotein, CA19.9 and bhCG), negative cervical and pelvic ultrasound, negative computed tomography of thorax and negative abdominal MRI. Bilateral and simultaneous petrosal inferior sinus sampling with desmopressin confirmed EAS due to negative central to peripheral ACTH gradient, even after normalized PRL/ACTH gradients. Finally, PET/CT with Ga68-DOTATATE revealed a single infracarinal nodule of 1.5x0.6 cm with high capture of radioligand, SUVmax of 23.2, suggestive of affected mediastinal lymph node. The patient was submitted to thoracic surgery and the infracarinal lymph node was dissected and removed. Anatomopathological and immunohistochemical analyses disclosed a lymph node metastatic of a well-differentiated grade neuroendocrine tumor ACTH positive, Ki-67 2%. After surgery, the patient exhibited CS improvement and impressive drop of hormones at 5th postsurgical day (serum cortisol <1.0 µg/dL and ACTH of 2.2 pg/mL) confirming remission of CS. CONCLUSION: To our knowledge, approximately 36 cases of EAS due to neuroendocrine tumor of unknown primary origin were reported. However, previous cases commonly exhibited no remission after only removal of metastasis. Our case presented initial remission even with no primary tumor identified (occult primary tumor non-functioning?). Follow up with clinical, hormonal and imaging methods are necessary due to recurrence risk. Presentation: Thursday, June 15, 2023

Open article ↗



2019-10-09 | Cushing Syndrome: The Role of MSCs in Wound Healing, Immunosuppression, Comorbidities, and Antioxidant Imbalance

Cushing syndrome (CS), caused by glucocorticoid (GCs) excess, is strictly connected to onset of different metabolic diseases and impaired wound healing. The source of excessively high levels of GCs allows the identification of endogenous and exogenous (iatrogenic) CS. Iatrogenic patients usually receive also anti-metabolites serving as the foundation to modern steroid-sparing immunosuppressive therapy. Tissues mainly targeted by CS are bone and fat, both derived from progenitor cells named mesenchymal stem cells (MSCs). In addition, the pathogenic role of MSCs in other diseases sharing common properties with CS, such as an altered inflammatory profile and increased oxidative stress, has been identified. In this light, MSCs isolated from skin of control healthy subjects (C-MSCs), patients affected by endogenous CS (ENDO-MSCs), patients affected by iatrogenic CS (IATRO-MSCs) and patients affected by exogenous CS receiving steroid-sparing drugs (SS-MSCs), respectively, have been isolated and analyzed. ENDO- and IATRO-MSCs showed a reduced differentiative potential toward osteogenic and adipogenic lineages compared to C-MSCs, whereas SS-MSCs re-acquired the ability to differentiate, with a trend similar to control cells. In addition, MSCs from CS groups, compared to control MSCs, displayed a reduction in the secretion of cytokines (immune-suppression), a decreased expression of genes related to wound healing and a dysregulation of the enzymes/genes related to antioxidant capacity. In conclusion, our results suggest that the hallmarks of CS, such as wound healing impairment and immunosuppression, are already detectable in undifferentiated cells, which could be considered a potential therapeutic early target for control of CS.

Open article ↗



2011-06-28 | Moving toward personalized cell-based interventions for adrenal cortical disorders: Part 2 — Human diseases and tissue engineering

Transdifferentiation of an individual's own cells into functional differentiated cells to replace an organ's lost function would be a personalized approach to therapeutics. In this two part series, we will describe the progress toward establishing functional transdifferentiated adrenal cortical cells. In this article (Part 2), we describe the disorders of the adrenal cortex, therefore establishing why there is the need for personalized cell-based therapy for individuals with these disorders. We then present our pilot studies of cell transdifferentiation toward an adrenal cortical fate using genes described in the first article of this pair (Part 1).

Open article ↗



1987-11-17 | Cushing's syndrome caused by an ectopic pituitary adenoma.

A 49-year old woman with a 5-year history of Cushing's syndrome was evaluated. Biochemical measurements revealed high cortisol and adrenocorticotropic hormone (ACTH) levels consistent with the ACTH-dependent type of Cushing's syndrome. However, the source of ACTH seemed to be autonomous as she demonstrated abnormal feedback control, with lack of response to metyrapone and high coses of dexamethasone. A search for an ectopic ACTH-secreting nonpituitary neoplasm was unsuccessful. Transsphenoidal pituitary exploration revealed a normal pituitary gland, but an ectopic pituitary adenoma was found incidentally in the mucosa of the sphenoid sinus. This adenoma stained strongly positive for ACTH on immunocytochemical studies. Resection of this lesion led to remission of the Cushing's syndrome. This variant of ACTH-dependent Cushing's syndrome can mimic the ectopic ACTH-dependent type and should be looked for in patients who fail to respond to pituitary operation.

Open article ↗



proteins
2026-08-01 | EP1247 - ECE_3606 - ACTH-dependent Cushing's syndrome: diagnostic pitfalls and personalised treatment strategies: a case series

Abstract Introduction Cushing's syndrome (CS) is caused by increased cortisol production from the adrenals or by ACTH secretion from a pituitary tumour (Cushing disease – CD) or non-pituitary tumour (ectopic secretion), leading to increased morbidity and mortality. The first line of treatment is surgery, but medical treatment, radiation or bilateral adrenalectomy are needed for recurrences or inoperable lesions. Objective and Methods To present the therapeutic challenges and individualised treatment options in 3 patients with ACTH-dependent CS, treated in a tertiary centre. Results The first patient is a 61-year-old female with a microprolactinoma (responsive to low-dose cabergoline), who developed CD due to a second pituitary microadenoma 10 years later, complicated with obesity, hypertension, diabetes mellitus, dyslipidaemia. Inferior petrosal sinus sampling was not available for the lateralisation of the ACTH secretion – she underwent selective neurosurgery on the biggest lesion followed by a second surgery due to persistent hypercortisolism, with a resolution of the CD and the metabolic syndrome. Three years later, CD relapsed, without identifiable pituitary or ectopic lesions on imaging. Low-dose pasireotide was initiated, with biochemical control and favourable metabolic evolution. The second patient is a 51-year-old woman with an invasive non-functioning pituitary macrodenoma, who underwent 2 partial adenomectomies and radiotherapy. Thirteen years later tumour progression was accompanied by the development of CD and metabolic complications – she underwent a third surgery, with persistent hypercortisolism. Pasireotide achieved cortisol control, but the diabetes worsened, therefore she was switched to ketoconazole, with a good biochemical and metabolic response. The third patient is a 67-year-old woman with a florid Cushing phenotype, weight loss, hypokalaemia, markedly elevated cortisol, ACTH and DHEAS levels. Extensive imagery (pituitary, chest and abdomen) came back negative, with the exception of a small indeterminate renal lesion. The somatostatin receptor scintigraphy and the inferior petrosal sinus sampling also failed to localise the ACTH source. She was initially started on ketoconazole, with a partial biochemical response, therefore she was switched to osilodrostat with a good clinical and hormonal evolution. She was referred to Nephrology for a renal biopsy, given the severe initial clinical and biochemical profile, suggesting a possible ectopic ACTH secretion (even though the scintigraphy was negative). Conclusion ACTH-dependent CS remains a complex condition with significant challenges, particularly in recurrent disease, aggressive pituitary tumours or occult ectopic ACTH secretion. These cases underscore the importance of a personalised approach and demonstrate the expanding role of medical therapies when surgical cure is not attainable.

Open article ↗



2026-07-23 | Fourteen-year bridge to cure in occult ectopic ACTH syndrome: resection of a 3-mm pulmonary carcinoid.

Ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) often involves occult microtumors, making localization challenging. We report a 68-year-old woman with severe ACTH-dependent hypercortisolism in whom the primary tumor remained occult despite extensive imaging, including 68Ga-tetraazacyclododecanetetraacetic acid-D-Phe(1)-Tyr(3)-octreotide positron emission tomography/computed tomography. Based on a positive octreotide challenge test, she received long-acting release octreotide for over a decade, achieving sustained biochemical stability. In 2020, she developed breast cancer, with the tumor being ACTH-negative on immunohistochemistry. In 2023, during resection of pulmonary metastases of the breast cancer, a 3-mm nodule was incidentally discovered in the adjacent lung tissue. Through close interdisciplinary coordination, the nodule was removed and was confirmed as an ACTH- and somatostatin receptor (SSTR) 2-positive pulmonary carcinoid. Thereafter, the EAS resolved completely with prompt recovery of adrenal function. In this case, intensive medical stabilization in occult EAS probably served as a strategic "bridge to surgery." Importantly, long-term biochemical control using somatostatin analogs facilitated prompt recovery of the hypothalamic-pituitary-adrenal axis immediately after tumor resection. This may also have preserved SSTR2 expression, potentially by mitigating cortisol-induced receptor downregulation, facilitating its eventual localization. This report shows that meticulous multidisciplinary communication during unrelated surgical procedures is indispensable for identifying radiologically occult lesions.

Open article ↗



2025-05-26 | A case series of bilateral inferior petrosal sinus sampling using desmopressin for evaluation of ACTH-dependent cushing's syndrome in pediatric patients: insights from Iran.

Pediatric Cushing Syndrome (CS) is rare and difficult to diagnose, especially when distinguishing ACTH-dependent subtypes. Bilateral inferior petrosal sinus sampling (BIPSS) is an essential but technically challenging procedure for this purpose. Because corticotropin-releasing hormone (CRH), the standard stimulant, has limitations, desmopressin is being explored as an alternative. This study assesses desmopressin-stimulated BIPSS for its diagnostic accuracy and tumor localization in pediatric CS within an Iranian cohort, addressing a gap in pediatric-specific diagnostic strategies and offering insights into the applicability of desmopressin in this context. Four pediatric patients with inconclusive pituitary imaging and suspected Cushing's disease (CD) underwent BIPSS with desmopressin at Taleghani Hospital, Tehran, Iran, between August 2015 and March 2019. Sensitivity of BIPSS for CD diagnosis was assessed, and tumor localization accuracy was evaluated during surgery. Bilateral IPSS demonstrated a sensitivity of 100% for diagnosing CD in pediatric patients. However, accuracy for tumor lateralization was moderate, with only 50% concordance between BIPSS lateralization and surgical findings. Specifically, two out of four patients had correct lateralization confirmed during surgery, while one patient with left lateralization was consistent with hypophysectomy findings. These discrepancies highlight challenges such as anatomical and drainage variations that can lead to mislocalization. Desmopressin enhances the sensitivity of BIPSS for diagnosing pediatric CD, presenting as a viable alternative to CRH stimulation. Despite high sensitivity, caution is advised when interpreting BIPSS results for tumor localization. Further research is needed to optimize diagnostic strategies for pediatric CS management.

Open article ↗



2025-03-27 | Sex-dependent effects of FGF21 on HPA axis regulation and adrenal regeneration after Cushing syndrome in mice

BACKGROUND: Cushing's syndrome (CS) results from prolonged exposure to excessive glucocorticoids (GCs), leading to metabolic disturbances and adrenal insufficiency (AI). Fibroblast growth factor 21 (FGF21) has shown promise as a potential therapeutic target for metabolic disorders. This study explores the effects of FGF21 on adrenal gland function in a mouse model of AI following chronic hypercortisolism and investigates sex-dependent differences in the hypothalamic-pituitary-adrenal (HPA) axis response. METHODS: We employed a mouse model of AI after chronic corticosterone (CORT) treatment. The effects of recombinant human FGF21 (hFGF21) administration on adrenal function were evaluated in AI mice. Male and female wild-type (WT) and FGF21-overexpressing transgenic (Tg) mice were subjected to 5 weeks of CORT treatment, reaching CS phenotype, followed by immediate analysis or a 10-week recovery period. Metabolic parameters, HPA axis function, and adrenal gland morphology and gene expression were assessed. RESULTS: Prolonged CORT exposure resulted in metabolic disturbances and HPA axis dysregulation. hFGF21 treatment increased CORT and ACTH secretion in AI mice. FGF21 overexpression influenced glucose homeostasis and insulin regulation during CORT treatment and recovery, with sex-specific effects. Tissue-specific regulation of Klb expression was observed across the HPA axis, with distinct patterns between males and females. Tg mice displayed altered adrenal progenitor cell activation and steroidogenic gene expression. Sex-specific differences were observed in adrenal capsule remodeling and gene expression patterns during recovery. CONCLUSIONS: This study reveals the complex interplay between FGF21 signaling and GC-induced metabolic and endocrine changes, suggesting a potential sex-specific role of FGF21 in metabolic regulation and HPA axis recovery following after CS.

Open article ↗



2025-01-30 | Performance of Vasopressin Stimulated Bilateral Inferior Petrosal Sinus Sampling in Corticotropin Dependent Cushing's Syndrome with Negative or Equivocal 3 Tesla Contrast Enhanced Magnetic Resonance Imaging of Pituitary.

Corticotropin releasing hormone (CRH)-stimulated bilateral inferior petrosal sinus sampling (BIPSS) is the most accurate procedure in the differential diagnosis of adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome (CS) with a sensitivity of 88-100% and a specificity of 67-100%. However, CRH is not available globally currently. We undertook this study of BIPSS using lysine vasopressin (LVP) as an agent to stimulate the release of ACTH from corticotrophs. Our objective was to assess the accuracy of LVP-stimulated BIPSS in differentiating Cushing's disease (CD) from ectopic ACTH syndrome (EAS) with negative or equivocal 3T contrast-enhanced MRI (CEMRI). Seventeen patients with clinically and biochemically confirmed ACTH-dependent CS with equivocal or negative CEMRI pituitary underwent BIPSS using LVP as a stimulating agent. Of seventeen patients who underwent BIPSS, nine patients had a raised central-to-peripheral ACTH ratio and were classified as having CD that was confirmed on histopathology following transsphenoidal sinus surgery. Remaining eight patients, who did not show a raised central-to-peripheral ACTH ratio, were classified to have EAS. All patients with EAS underwent contrast-enhanced computerised tomography of the neck, chest, and abdomen and/or Gallium 68 DOTANOC positron emission tomography/computerised tomography. Seven out of eight patients demonstrated solitary pulmonary nodule in the lung (bronchial carcinoid), and one patient had a mass in the thymus (thymic carcinoid). BIPSS using LVP confirmed the source of ACTH excess correctly in all the patients with ACTH-dependent CS without the loss of specificity.

Open article ↗



antibodies
2022-06-22 | Successful Immunomodulatory Treatment of COVID-19 in a Patient With Severe ACTH-Dependent Cushing’s Syndrome: A Case Report and Review of Literature

Introduction Patients with Cushing’s syndrome (CS) represent a highly sensitive group during corona virus disease 2019 (COVID-19) pandemic. The effect of multiple comorbidities and immune system supression make the clinical picture complicated and treatment challenging. Case report A 70-year-old female was admitted to a covid hospital with a severe form of COVID-19 pneumonia that required oxygen supplementation. Prior to her admission to the hospital she was diagnosed with adrenocorticotropic hormone (ACTH)-dependent CS, and the treatment of hypercortisolism had not been started yet. Since the patient’s condition was quickly deteriorating, and with presumend immmune system supression due to CS, we decided on treatement with intraveonus immunoglobulins (IVIg) that enabled quick onset of immunomodulatory effect. All comorbidities were treated with standard of care. The patient’s condition quickly stabilized with no direct side effects of a given treatment. Conclusion Treatment of COVID-19 in patients with CS faces many challenges due to the complexity of comorbidity effects, immunosupression and potential interactions of available medications both for treatment of COVID-19 and CS. So far, there are no guidelines for treatment of COVID-19 in patients with active CS. It is our opinion that immunomodulating therapies like IVIg might be an effective and safe treatment modality in this particularly fragile group of patients.

Open article ↗



2019-06-05 | A Long-Acting Neutralizing Monoclonal ACTH Antibody Blocks Corticosterone and Adrenal Gene Responses in Neonatal Rats

The control of steroidogenesis in the neonatal adrenal gland is of great clinical interest. We have previously demonstrated that the postnatal day (PD) 2 rat exhibits a large plasma corticosterone response to hypoxia in the absence of an increase in plasma ACTH measured by RIA, whereas the corticosterone response to exogenous ACTH is intact. By PD8, the corticosterone response to hypoxia is clearly ACTH-dependent. We hypothesized that this apparently ACTH-independent response to hypoxia in the newborn rat is due to an increase in a bioactive, nonimmunoassayable form of ACTH. To evaluate this phenomenon, we pretreated neonatal rats with a novel, specific, neutralizing anti-ACTH antibody (ALD1611) (20 mg/kg or 1 mg/kg IP) on the morning of PD1, PD7, and PD14. Twenty-four hours later, we measured hypoxia- or ACTH-stimulated plasma ACTH and corticosterone. For long-term effects, ALD1611 was given on PD1 and pups were studied on PD8 and PD15. Pretreatment with ALD1611 significantly decreased baseline corticosterone and completely blocked the corticosterone response to hypoxia and exogenous ACTH stimulation at all ages. The effect of 1 mg/kg ALD1611 on PD1 had dissipated by PD15. The decrease in corticosterone in ALD1611-treated pups was associated with decreases in baseline and hypoxia- and ACTH-stimulated adrenal Ldlr, Mrap, and Star mRNA expression at all ages. The adrenal response to hypoxia in the newborn rat is ACTH-dependent, suggesting the release of nonimmunoassayable, biologically active forms of ACTH. ALD1611 is useful as a tool to attenuate stress-induced, ACTH-dependent adrenal steroidogenesis in vivo.

Open article ↗



2018-08-23 | Glucocorticoid-induced insulin resistance is related to macrophage visceral adipose tissue infiltration

Insulin resistance is frequently present in patients with glucocorticoid (GC) excess (Cushing’s syndrome) or treated with high doses of GCs. Furthermore, others similarities between metabolic syndrome (visceral obesity, elevated blood glucose levels, dyslipidemia) and Cushing’s syndrome suggest that GCs could play a role in obesity-linked complications. Here we reported that long-term corticosterone (CORT) exposure in mice induced weight gain, dyslipidemia as well as hyperglycaemia and systemic insulin resistance. CORT-treated mice exhibited an increased 11β-Hsd1 expression and corticosterone levels in fat depots but a specific upregulation of glucocorticoid receptor (Gr) and hexose-6-phosphate dehydrogenase only in gonadal adipose tissue, suggesting that GC could act differentially on various fat depots. Despite fat accumulation in all depots, an increased expression of adipogenic (Pparγ, C/ebpα) and lipogenic (Acc, Fas) key genes was restricted to gonadal adipose tissue. Hypertrophied adipocytes observed in both visceral and subcutaneous depots also resulted from reduced lipolytic activity due to CORT treatment. Surprisingly, GC treatment promoted macrophage infiltration (F4/80, Cd68) within all adipose tissues along with predominant M2-like macrophage phenotype, and can directly act on macrophages to induce this phenotype. Moreover, macrophage infiltration preceded mass gain and adipocyte hypertrophy. Of note, specific macrophage depletion in gonadal fat preferentially reduced the M2-like macrophage content, and partially restored insulin sensitivity in mice with GC-induced obesity and insulin resistance. These data provide evidence that GCs act on adipose tissue in a depot-dependent manner and that gonadal adipose macrophages are key effectors of GC-associated insulin resistance.

Open article ↗



2017-02-20 | Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals

Increased cortisol levels in obesity may contribute to the associated metabolic syndrome. In obesity, the activated innate immune system leads to increased interleukin (IL)-1β, which is known to stimulate the release of adrenocorticotropin hormone (ACTH). We hypothesized that in obesity IL-1 antagonism would result in downregulation of the hypothalamo-pituitary-adrenal axis, leading to decreased cortisol levels. In this prospective intervention study, we included 73 patients with obesity (body mass index [BMI] ≥30 kg/m2) and at least one additional feature of the metabolic syndrome. The primary end point was change in morning cortisol from baseline to after the administration of the IL-1 receptor antagonist (anakinra/Kineret®, total dose 3 × 100 mg). Secondary end points were effects on salivary cortisol and ACTH. Median age was 56 years, 50.7% of patients were female, and median BMI was 36.3 kg/m2. Median morning serum cortisol levels (nmol/L) decreased significantly after IL-1 antagonism [from baseline, 452 to 423; absolute difference, −38.7; 95% confidence interval (CI), −64 to −13.4; P = 0.0019]. Similar effects were found for salivary cortisol levels (−2.8; 95% CI, −4.4 to −1.3; P = 0.0007), ACTH levels (−2.2; 95% CI; −4.2 to −0.1; P = 0.038), systolic blood pressure (−5.2, 95% CI, −8.5 to −1.8; P = 0.0006), and heart rate (−2.9; 95% CI, −4.7 to −1.0; P = 0.0029). IL-1 antagonism in obese individuals with features of the metabolic syndrome leads to a decrease in serum cortisol, salivary cortisol, and ACTH levels along with a reduction in systolic blood pressure and heart rate.

Open article ↗



1994-04-01 | The value of inferior petrosal sinus sampling in diagnosis and treatment of Cushing's disease

Summary OBJECTIVE While microsurgical selective adenomectomy is the best method available at present for the treatment of Cushing's disease, its success depends to a large degree on precise preoperative intrapituitary microadenoma localization. This study compares the results of intrapituitary adenoma localization obtained with inferior petrosal sampling, computerized tomography and magnetic resonance imaging with the adenoma localization as found at surgery. DESIGN The results of inferior petrosal sampling for intrapituitary localization of ACTH‐producing pituitary adenomas were compared in a retrospective study with the results of computerized tomography, magnetic resonance imaging, surgical and pathological findings. Special attention was paid to the intersinus ACTH relation. PATIENTS Thirty‐eight patients (33 women and 5 men) of 11‐68 years of age suffering from pituitary‐dependent Cushing's disease were studied. Patients with ectopic ACTH‐secreting tumours and and recurrent pituitary adenomas were excluded. MEASUREMENTS Blood samples were obtained simultaneously from both inferior petrosal sinuses and a peripheral vein before and 5, 10, 15 and 20 minutes after stimulation with 60 /μg/m 2 human corticotrophin‐releasing hormone (hCRH). RESULTS of the adenomas in our series, 42% had a diameter of 3 mm or less. Only 6 of 20 adenomas examined by computerized tomography and 11 of 29 examined by magnetic resonance imaging were identified correctly. Inferior petrosal sinus sampling produced significantly better results, particularly when combined with a stimulation test with hCRH: for 29 of 38 adenomas examined, the location was predicted correctly with these techniques. Analysis of the intersinus adrenocorticotrophin concentration ratio showed that the best right‐central‐left discrimination was obtained with values of 1.3 and 1.4. CONCLUSIONS We conclude that inferior petrosal sinus ACTH sampling after hCRH stimulation is the best method available for the intrapituitary localization of microadenomas causing Cushing's disease provided that the appropriate technique of blood sampling is used meticulously.

Open article ↗



small molecules
2026-09-22 | Conversion therapy followed by curative resection in a patient with ACTH-secreting pancreatic neuroendocrine tumor G3: a case report

Background Pancreatic neuroendocrine tumors (pNETs) with ectopic adrenocorticotropic hormone (ACTH) production are uncommon, highly aggressive, and carry a dismal prognosis. Early nonspecific symptoms often delay diagnosis, and treatment strategies remain controversial. For patients with locally advanced pNETs, conversion therapy has only rarely been reported and remains a sparingly applied strategy. Case presentation A 37-year-old woman presented with a six-month history of progressive swelling in both lower extremities and her face. Further workup confirmed ACTH-dependent Cushing syndrome. CT and MRI identified a 5.7 × 2.8 cm lesion in the pancreatic body/tail that invaded the left adrenal gland and splenic vessels, accompanied by retroperitoneal lymph node spread. Biopsy results indicated a G3 pNET. Given the borderline resectable status due to local advancement, she received conversion therapy comprising a long-acting somatostatin analogue followed by CapTem chemotherapy. After three months of neoadjuvant treatment, imaging showed modest primary tumor shrinkage and marked reduction of lymph node size, reflecting successful downstaging. Subsequently, she underwent distal pancreatectomy with splenectomy, left adrenalectomy, and lymph node dissection, achieving R0 resection. Final pathology confirmed a G3 pNET (Ki-67 30%–40%) with positive SSTR2 and ACTH immunostaining. Although the patient eventually experienced disease progression and succumbed to COVID-19 infection 37 months after initial diagnosis, this case illustrates that conversion therapy can render an initially borderline resectable high-grade pNET amenable to curative resection. Conclusion This report underscores the aggressive trajectory of ACTH-secreting pNET G3 and suggests the potential utility of conversion therapy. Further studies are needed to validate this approach.

Open article ↗



2026-09-03 | Metyrapone in the Management of Severe Hypercortisolism Secondary to Ectopic Cushing's Syndrome.

Ectopic Cushing's syndrome (ECS) is a rare but important cause of ACTH-dependent Cushing's syndrome. Metyrapone, a steroidogenesis inhibitor targeting 11-β hydroxylase, has shown effectiveness in controlling hypercortisolism. However, little is known about the practical aspects of its initiation, use, and effectiveness in ECS. We present three cases of severe hypercortisolism secondary to ECS managed with metyrapone and report our experience. Case 1: a 56-year-old male with high-grade neuroendocrine carcinoma. Case 2: a 67-year-old man with a history of stage IIB non-small cell lung cancer (NSCLC) with metastatic neuroendocrine carcinoma. Case 3: a 64-year-old man with metastatic prostate cancer. Biochemical control was achieved with rapid titration of low doses of daily metyrapone in all three cases. Based on our experience, we recommend an initial dose of 1000-1500 mg of metyrapone daily, in divided doses, with physiologic glucocorticoid replacement to mitigate the risk of adrenal insufficiency. Despite improvements in cortisol levels and stabilization of metabolic derangements, all three patients ultimately transitioned to comfort-focused care. Given the rarity, heterogeneity, and aggressiveness of this condition, rapid diagnosis and standardized pharmacologic approach are difficult to achieve. More data are needed to guide optimal therapy selection, dosing, and titration in ECS.

Open article ↗



2026-08-13 | Ectopic ACTH-dependent Cushing syndrome in 3 hospitalized patients: lessons learned from management with osilodrostat.

Severe Cushing syndrome (CS) is a rare diagnosis with high mortality, which limits the ability of endocrinologists to gain experience delivering care. Here we describe our experience treating 3 cases of ectopic ACTH-dependent CS presenting in a single year. The initial diagnosis of each case was made during hospitalization resulting from complications of CS, implicating severe disease and delayed diagnosis. Our experience suggests that rapid initiation and titration of osilodrostat effectively treats hypercortisolism and improves outcomes.

Open article ↗



2026-08-01 | P246 - ECE_3578 - Osilodrostat in a block-and-replace strategy for successful management of cycling Cushing’s syndrome—case series

Abstract Introduction Cyclic Cushing’s syndrome (cCS) represents a significant clinical challenge due to unpredictable fluctuations in cortisol secretion, leading to heterogenous presentations and false-negative biochemical results. Although previously considered rare, cCS is increasingly recognized in clinical practice. Management is particularly difficult, and block-and-replace therapy with osilodrostat may provide effective cortisol stabilization. We present two illustrative cases from our clinic, highlighting the diagnostic process and practical use of osilodrostat in a block-and-replace strategy among patients with cCS. Case presentations A 68-year-old man with a 5-year history of recurrent hospitalizations due to infections and metabolic instability evaluated for bilateral adrenal incidentalomas. The patient presented with cushingoid features, and biochemical tests confirmed ACTH-dependent CS. Despite extensive imaging, the source of ACTH excess could not be identified. Retrospective analysis of the patient's history revealed multiple peaks of hypercortisolemia (morning serum cortisol 34.43-43.5 ug/dl) separated by spontaneous remissions (morning serum cortisol 8.02-13.3 ug/dl), correlating with episodes of hypertension and hyperglycemia, followed by hypotension and hypoglycemia. He was treated with metyrapone, temporarily in a block-and-replace regimen, however, marked cortisol variability required frequent dose adjustments. Initiation of low-dose osilodrostat (1 mg) in a continuous block-and-replace regimen (with hydrocortisone 5-10 mg daily) resulted in sustained biochemical and clinical stabilization for 13 months. Osilodrostat was discontinued prior to planned BIPSS, with the patient maintained on hydrocortisone replacement. Currently, the patient remains in an eucortisolemic phase 11 months after osilodrostat discontinuation. A 45-year-old woman was admitted after referral by her gynecologist, presenting with numerous cushingoid features, worsening hypertension, and diabetes. Biochemical and imaging tests confirmed Cushing’s disease (CD), leading to transsphenoidal surgery. She remained on hydrocortisone for six years, with several unsuccessful discontinuation attempts. Ambulatory cortisol measurements suggested normocortisolemia (morning serum cortisol 12.7-15.3 ug/dl), but during admissions for planned discontinuation, they were unexpectedly low (morning serum cortisol 3.6-7.66 ug/dl). After eventual adrenal function recovery, she experienced fluctuating control of comorbidities. BIPSS performed during peak of hypercortisolemia confirmed recurrent CD, and pituitary radiotherapy was performed. Block-and-replace therapy with osilodrostat was initiated at 4 mg daily with hydrocortisone 5-10 mg. Optimal disease control enabled dose reductions, with the patient currently stable on 1 mg of osilodrostat and 5 mg of hydrocortisone. Conclusions These cases illustrate the complexity of diagnosing and managing cCS. In both patients, the block-and-replace therapy with osilodrostat was well tolerated, effectively stabilized cortisol concentrations and controlled comorbidities, demonstrating its clinical value and safety in real-life management of cCS.

Open article ↗



2026-08-01 | EP1814 - LBA_ECE_1433 - Multimodal management of silent corticotroph tumors with Crooke's cell features transforming into severe Cushing's disease—the ERCUSYN Kraków cohort

Abstract Background Silent corticotroph tumors (SCTs) are pituitary neuroendocrine tumors of corticotroph lineage characterized by T-PIT positivity without clinical or biochemical hypercortisolism at diagnosis. Transforming into overt ACTH-dependent Cushing's disease (CD) has been reported in approximately 4% of cases, representing a rare but clinically significant phenomenon. Methods We report three patients from the ERCUSYN Kraków cohort with initially silent corticotroph PitNETs with Crooke's cell features who subsequently developed overt CD during long-term follow-up. Results A 53-year-old woman underwent resection of a nonfunctioning pituitary macroadenoma measuring up to 40 mm. Histopathology demonstrated a densely granulated corticotroph tumor with scattered Crooke's cells (Ki-67 approximately 3%). Proton radiotherapy was subsequently performed. Six years later, rapid tumor progression involving the sella and left cavernous sinus was observed together with biochemical ACTH-dependent hypercortisolism (loss of circadian rhythm, late-night cortisol 19.3 µg/dL, urinary free cortisol 308-445 µg/24 h, ACTH 97.7 pg/mL), despite only mild clinical manifestations. The progression was accompanied by severe mass-effect symptoms, including visual field impairment, ptosis, and convergent strabismus. Combination therapy with pasireotide LAR and temozolomide was initiated. Temozolomide was discontinued after the first cycle due to bone marrow aplasia, while continued pasireotide therapy resulted in radiological stabilization and normalization of cortisol levels. An 80-year-old man underwent incomplete transsphenoidal resection of a 35 mm nonfunctioning macroadenoma (Knosp grade 2). Histopathology confirmed a corticotroph PitNET with Crooke's cell features, followed by adjuvant radiotherapy. Approximately nine years later, the patient developed clinically overt ACTH-dependent CS without significant radiological tumor progression. Initial treatment with pasireotide was insufficient. Due to severe hypercortisolism, osilodrostat was initiated directly in a block-and-replace regimen (up to 30 mg/d) with hydrocortisone supplementation, resulting in biochemical remission and clinical improvement. A 71-year-old woman underwent four transsphenoidal resections of a corticotroph macroadenoma within two years followed by radiotherapy. Five years later, marked tumor progression (Knosp grade 4) occurred with severe mass-effect symptoms including convergent strabismus and impaired ocular motility. Treatment with pasireotide and temozolomide was initiated; however, overt CD developed during therapy. Osilodrostat was introduced and administered for six months, achieving biochemical control of hypercortisolism. Subsequently, temozolomide therapy was continued, and after seven cycles the patient remains clinically stable with radiological tumor regression. Conclusions SCTs with Crooke's cell features may transform into severe CD many years after the initial diagnosis, sometimes even without marked radiological progression. These observations highlight the importance of long-term endocrine surveillance and often necessitate multimodal therapeutic strategies including surgery, radiotherapy, and targeted medical therapy.

Open article ↗



cell therapies
2026-06-12 | ACTH-dependent Cushing's syndrome in MEN1: When multiple tumors complicate the diagnosis.

ACTH-dependent Cushing's syndrome (CS) is a rare manifestation of multiple endocrine neoplasia type 1 (MEN1). Identifying the ACTH source is challenging in MEN1 due to the frequent coexistence of multiple synchronous neuroendocrine tumors (NETs) in these patients. We describe the diagnostic dilemma in a 51-year-old male with MEN1 and severe ACTH-dependent CS. To analyze the specific diagnostic pitfalls in this population, we conducted a systematic literature review focusing exclusively on documented cases of ectopic Cushing syndrome (ECS) in MEN1 patients. The patient presented severe CS, with urinary free cortisol (UFC) at 3,188μg/24h (exceeding 25 times the upper limit of normal). Rapid biochemical control was achieved within 10 days using a high-dose (60mg/day) osilodrostat "block-and-replace" regimen. Imaging identified 3 potential sources: a 7×8mm pituitary microadenoma, a small pancreatic NET, and a large thymic NET (48×62×67mm). Despite a desmopressin stimulation test falsely suggesting a pituitary source (+118% ACTH increase), clinical severity and imaging indicated total thymectomy. Pathology confirmed a typical carcinoid tumor with ACTH expression. Postoperatively, the patient achieved complete remission. Our review of ectopic Cushing's syndrome (ECS) in MEN1 identified a total of 18 cases to date. Thymic NETs were the most frequent source (61%), followed by pancreatic NETs (28%). Notably, ectopic secretion of corticotropin-releasing hormone (CRH) was identified in 4 cases (22%), constituting a major diagnostic pitfall that led to unnecessary transsphenoidal surgery in 3 cases. ACTH-dependent CS in MEN1 is a diagnostic "perfect storm", where pituitary incidentalomas frequently mislead clinicians. Based on our review, ectopic CRH or ACTH secretion from thoracic or abdominal NETs must be systematically considered. We advocate a strategy prioritizing resection of the most suspicious lesion identified on imaging, thereby avoiding unnecessary transsphenoidal surgery.

Open article ↗



2023-10-01 | THU014 Post-surgical Remission After Resection Of Solitary Mediastinal Lymph Node In A Metastatic Occult Ectopic ACTH Syndrome Patient

Abstract Disclosure: I.P. de Magalhães: None. C.P. Oliveira: None. L.P. Lins: None. N.X. Andrade: None. M.S. Lima: None. S.A. Siqueira: None. J.S. Fonini: None. E.C. Assis Filho: None. A.W. Mariani: None. M.C. Machado: None. BACKGROUND: The prevalence of occult cases has been increasing in the most recent series of Ectopic ACTH syndrome (EAS) maybe due to the small size of pulmonary neuroendocrine tumors. We present an atypical and very rare case of EAS with initial presentation of a single metastatic mediastinal lymph node that evolved with remission after your resection with no defined primary tumor. CASE REPORT: A 15-year-old female patient presented a clinical feature of Cushing’s syndrome (CS) with a 1-year evolution. Hormonal evaluation confirmed ACTH-dependent CS: urinary free cortisol of 819 µg/24h (3-43), late night salivary cortisol of 409 ng/dL (<274) and ACTH of 105 pg/mL (<63.3). Noninvasive methods for differential diagnosis of ACTH-dependent CS did not clarify the etiology (conflicting results): pituitary MRI negative, suppression of 59.6% of cortisol after high dose dexamethasone suppression test, positive response of ACTH and cortisol at desmopressin test, suppression of 81% of ACTH at acute octreotide SC test, negative serum tumor markers (gastrin, calcitonin, CEA, CA125, alpha-fetoprotein, CA19.9 and bhCG), negative cervical and pelvic ultrasound, negative computed tomography of thorax and negative abdominal MRI. Bilateral and simultaneous petrosal inferior sinus sampling with desmopressin confirmed EAS due to negative central to peripheral ACTH gradient, even after normalized PRL/ACTH gradients. Finally, PET/CT with Ga68-DOTATATE revealed a single infracarinal nodule of 1.5x0.6 cm with high capture of radioligand, SUVmax of 23.2, suggestive of affected mediastinal lymph node. The patient was submitted to thoracic surgery and the infracarinal lymph node was dissected and removed. Anatomopathological and immunohistochemical analyses disclosed a lymph node metastatic of a well-differentiated grade neuroendocrine tumor ACTH positive, Ki-67 2%. After surgery, the patient exhibited CS improvement and impressive drop of hormones at 5th postsurgical day (serum cortisol <1.0 µg/dL and ACTH of 2.2 pg/mL) confirming remission of CS. CONCLUSION: To our knowledge, approximately 36 cases of EAS due to neuroendocrine tumor of unknown primary origin were reported. However, previous cases commonly exhibited no remission after only removal of metastasis. Our case presented initial remission even with no primary tumor identified (occult primary tumor non-functioning?). Follow up with clinical, hormonal and imaging methods are necessary due to recurrence risk. Presentation: Thursday, June 15, 2023

Open article ↗



2019-10-09 | Cushing Syndrome: The Role of MSCs in Wound Healing, Immunosuppression, Comorbidities, and Antioxidant Imbalance

Cushing syndrome (CS), caused by glucocorticoid (GCs) excess, is strictly connected to onset of different metabolic diseases and impaired wound healing. The source of excessively high levels of GCs allows the identification of endogenous and exogenous (iatrogenic) CS. Iatrogenic patients usually receive also anti-metabolites serving as the foundation to modern steroid-sparing immunosuppressive therapy. Tissues mainly targeted by CS are bone and fat, both derived from progenitor cells named mesenchymal stem cells (MSCs). In addition, the pathogenic role of MSCs in other diseases sharing common properties with CS, such as an altered inflammatory profile and increased oxidative stress, has been identified. In this light, MSCs isolated from skin of control healthy subjects (C-MSCs), patients affected by endogenous CS (ENDO-MSCs), patients affected by iatrogenic CS (IATRO-MSCs) and patients affected by exogenous CS receiving steroid-sparing drugs (SS-MSCs), respectively, have been isolated and analyzed. ENDO- and IATRO-MSCs showed a reduced differentiative potential toward osteogenic and adipogenic lineages compared to C-MSCs, whereas SS-MSCs re-acquired the ability to differentiate, with a trend similar to control cells. In addition, MSCs from CS groups, compared to control MSCs, displayed a reduction in the secretion of cytokines (immune-suppression), a decreased expression of genes related to wound healing and a dysregulation of the enzymes/genes related to antioxidant capacity. In conclusion, our results suggest that the hallmarks of CS, such as wound healing impairment and immunosuppression, are already detectable in undifferentiated cells, which could be considered a potential therapeutic early target for control of CS.

Open article ↗



2011-06-28 | Moving toward personalized cell-based interventions for adrenal cortical disorders: Part 2 — Human diseases and tissue engineering

Transdifferentiation of an individual's own cells into functional differentiated cells to replace an organ's lost function would be a personalized approach to therapeutics. In this two part series, we will describe the progress toward establishing functional transdifferentiated adrenal cortical cells. In this article (Part 2), we describe the disorders of the adrenal cortex, therefore establishing why there is the need for personalized cell-based therapy for individuals with these disorders. We then present our pilot studies of cell transdifferentiation toward an adrenal cortical fate using genes described in the first article of this pair (Part 1).

Open article ↗



1987-11-17 | Cushing's syndrome caused by an ectopic pituitary adenoma.

A 49-year old woman with a 5-year history of Cushing's syndrome was evaluated. Biochemical measurements revealed high cortisol and adrenocorticotropic hormone (ACTH) levels consistent with the ACTH-dependent type of Cushing's syndrome. However, the source of ACTH seemed to be autonomous as she demonstrated abnormal feedback control, with lack of response to metyrapone and high coses of dexamethasone. A search for an ectopic ACTH-secreting nonpituitary neoplasm was unsuccessful. Transsphenoidal pituitary exploration revealed a normal pituitary gland, but an ectopic pituitary adenoma was found incidentally in the mucosa of the sphenoid sinus. This adenoma stained strongly positive for ACTH on immunocytochemical studies. Resection of this lesion led to remission of the Cushing's syndrome. This variant of ACTH-dependent Cushing's syndrome can mimic the ectopic ACTH-dependent type and should be looked for in patients who fail to respond to pituitary operation.

Open article ↗



proteins
2026-08-01 | EP1247 - ECE_3606 - ACTH-dependent Cushing's syndrome: diagnostic pitfalls and personalised treatment strategies: a case series

Abstract Introduction Cushing's syndrome (CS) is caused by increased cortisol production from the adrenals or by ACTH secretion from a pituitary tumour (Cushing disease – CD) or non-pituitary tumour (ectopic secretion), leading to increased morbidity and mortality. The first line of treatment is surgery, but medical treatment, radiation or bilateral adrenalectomy are needed for recurrences or inoperable lesions. Objective and Methods To present the therapeutic challenges and individualised treatment options in 3 patients with ACTH-dependent CS, treated in a tertiary centre. Results The first patient is a 61-year-old female with a microprolactinoma (responsive to low-dose cabergoline), who developed CD due to a second pituitary microadenoma 10 years later, complicated with obesity, hypertension, diabetes mellitus, dyslipidaemia. Inferior petrosal sinus sampling was not available for the lateralisation of the ACTH secretion – she underwent selective neurosurgery on the biggest lesion followed by a second surgery due to persistent hypercortisolism, with a resolution of the CD and the metabolic syndrome. Three years later, CD relapsed, without identifiable pituitary or ectopic lesions on imaging. Low-dose pasireotide was initiated, with biochemical control and favourable metabolic evolution. The second patient is a 51-year-old woman with an invasive non-functioning pituitary macrodenoma, who underwent 2 partial adenomectomies and radiotherapy. Thirteen years later tumour progression was accompanied by the development of CD and metabolic complications – she underwent a third surgery, with persistent hypercortisolism. Pasireotide achieved cortisol control, but the diabetes worsened, therefore she was switched to ketoconazole, with a good biochemical and metabolic response. The third patient is a 67-year-old woman with a florid Cushing phenotype, weight loss, hypokalaemia, markedly elevated cortisol, ACTH and DHEAS levels. Extensive imagery (pituitary, chest and abdomen) came back negative, with the exception of a small indeterminate renal lesion. The somatostatin receptor scintigraphy and the inferior petrosal sinus sampling also failed to localise the ACTH source. She was initially started on ketoconazole, with a partial biochemical response, therefore she was switched to osilodrostat with a good clinical and hormonal evolution. She was referred to Nephrology for a renal biopsy, given the severe initial clinical and biochemical profile, suggesting a possible ectopic ACTH secretion (even though the scintigraphy was negative). Conclusion ACTH-dependent CS remains a complex condition with significant challenges, particularly in recurrent disease, aggressive pituitary tumours or occult ectopic ACTH secretion. These cases underscore the importance of a personalised approach and demonstrate the expanding role of medical therapies when surgical cure is not attainable.

Open article ↗



2026-07-23 | Fourteen-year bridge to cure in occult ectopic ACTH syndrome: resection of a 3-mm pulmonary carcinoid.

Ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) often involves occult microtumors, making localization challenging. We report a 68-year-old woman with severe ACTH-dependent hypercortisolism in whom the primary tumor remained occult despite extensive imaging, including 68Ga-tetraazacyclododecanetetraacetic acid-D-Phe(1)-Tyr(3)-octreotide positron emission tomography/computed tomography. Based on a positive octreotide challenge test, she received long-acting release octreotide for over a decade, achieving sustained biochemical stability. In 2020, she developed breast cancer, with the tumor being ACTH-negative on immunohistochemistry. In 2023, during resection of pulmonary metastases of the breast cancer, a 3-mm nodule was incidentally discovered in the adjacent lung tissue. Through close interdisciplinary coordination, the nodule was removed and was confirmed as an ACTH- and somatostatin receptor (SSTR) 2-positive pulmonary carcinoid. Thereafter, the EAS resolved completely with prompt recovery of adrenal function. In this case, intensive medical stabilization in occult EAS probably served as a strategic "bridge to surgery." Importantly, long-term biochemical control using somatostatin analogs facilitated prompt recovery of the hypothalamic-pituitary-adrenal axis immediately after tumor resection. This may also have preserved SSTR2 expression, potentially by mitigating cortisol-induced receptor downregulation, facilitating its eventual localization. This report shows that meticulous multidisciplinary communication during unrelated surgical procedures is indispensable for identifying radiologically occult lesions.

Open article ↗



2025-05-26 | A case series of bilateral inferior petrosal sinus sampling using desmopressin for evaluation of ACTH-dependent cushing's syndrome in pediatric patients: insights from Iran.

Pediatric Cushing Syndrome (CS) is rare and difficult to diagnose, especially when distinguishing ACTH-dependent subtypes. Bilateral inferior petrosal sinus sampling (BIPSS) is an essential but technically challenging procedure for this purpose. Because corticotropin-releasing hormone (CRH), the standard stimulant, has limitations, desmopressin is being explored as an alternative. This study assesses desmopressin-stimulated BIPSS for its diagnostic accuracy and tumor localization in pediatric CS within an Iranian cohort, addressing a gap in pediatric-specific diagnostic strategies and offering insights into the applicability of desmopressin in this context. Four pediatric patients with inconclusive pituitary imaging and suspected Cushing's disease (CD) underwent BIPSS with desmopressin at Taleghani Hospital, Tehran, Iran, between August 2015 and March 2019. Sensitivity of BIPSS for CD diagnosis was assessed, and tumor localization accuracy was evaluated during surgery. Bilateral IPSS demonstrated a sensitivity of 100% for diagnosing CD in pediatric patients. However, accuracy for tumor lateralization was moderate, with only 50% concordance between BIPSS lateralization and surgical findings. Specifically, two out of four patients had correct lateralization confirmed during surgery, while one patient with left lateralization was consistent with hypophysectomy findings. These discrepancies highlight challenges such as anatomical and drainage variations that can lead to mislocalization. Desmopressin enhances the sensitivity of BIPSS for diagnosing pediatric CD, presenting as a viable alternative to CRH stimulation. Despite high sensitivity, caution is advised when interpreting BIPSS results for tumor localization. Further research is needed to optimize diagnostic strategies for pediatric CS management.

Open article ↗



2025-03-27 | Sex-dependent effects of FGF21 on HPA axis regulation and adrenal regeneration after Cushing syndrome in mice

BACKGROUND: Cushing's syndrome (CS) results from prolonged exposure to excessive glucocorticoids (GCs), leading to metabolic disturbances and adrenal insufficiency (AI). Fibroblast growth factor 21 (FGF21) has shown promise as a potential therapeutic target for metabolic disorders. This study explores the effects of FGF21 on adrenal gland function in a mouse model of AI following chronic hypercortisolism and investigates sex-dependent differences in the hypothalamic-pituitary-adrenal (HPA) axis response. METHODS: We employed a mouse model of AI after chronic corticosterone (CORT) treatment. The effects of recombinant human FGF21 (hFGF21) administration on adrenal function were evaluated in AI mice. Male and female wild-type (WT) and FGF21-overexpressing transgenic (Tg) mice were subjected to 5 weeks of CORT treatment, reaching CS phenotype, followed by immediate analysis or a 10-week recovery period. Metabolic parameters, HPA axis function, and adrenal gland morphology and gene expression were assessed. RESULTS: Prolonged CORT exposure resulted in metabolic disturbances and HPA axis dysregulation. hFGF21 treatment increased CORT and ACTH secretion in AI mice. FGF21 overexpression influenced glucose homeostasis and insulin regulation during CORT treatment and recovery, with sex-specific effects. Tissue-specific regulation of Klb expression was observed across the HPA axis, with distinct patterns between males and females. Tg mice displayed altered adrenal progenitor cell activation and steroidogenic gene expression. Sex-specific differences were observed in adrenal capsule remodeling and gene expression patterns during recovery. CONCLUSIONS: This study reveals the complex interplay between FGF21 signaling and GC-induced metabolic and endocrine changes, suggesting a potential sex-specific role of FGF21 in metabolic regulation and HPA axis recovery following after CS.

Open article ↗



2025-01-30 | Performance of Vasopressin Stimulated Bilateral Inferior Petrosal Sinus Sampling in Corticotropin Dependent Cushing's Syndrome with Negative or Equivocal 3 Tesla Contrast Enhanced Magnetic Resonance Imaging of Pituitary.

Corticotropin releasing hormone (CRH)-stimulated bilateral inferior petrosal sinus sampling (BIPSS) is the most accurate procedure in the differential diagnosis of adrenocorticotropic hormone (ACTH)-dependent Cushing's syndrome (CS) with a sensitivity of 88-100% and a specificity of 67-100%. However, CRH is not available globally currently. We undertook this study of BIPSS using lysine vasopressin (LVP) as an agent to stimulate the release of ACTH from corticotrophs. Our objective was to assess the accuracy of LVP-stimulated BIPSS in differentiating Cushing's disease (CD) from ectopic ACTH syndrome (EAS) with negative or equivocal 3T contrast-enhanced MRI (CEMRI). Seventeen patients with clinically and biochemically confirmed ACTH-dependent CS with equivocal or negative CEMRI pituitary underwent BIPSS using LVP as a stimulating agent. Of seventeen patients who underwent BIPSS, nine patients had a raised central-to-peripheral ACTH ratio and were classified as having CD that was confirmed on histopathology following transsphenoidal sinus surgery. Remaining eight patients, who did not show a raised central-to-peripheral ACTH ratio, were classified to have EAS. All patients with EAS underwent contrast-enhanced computerised tomography of the neck, chest, and abdomen and/or Gallium 68 DOTANOC positron emission tomography/computerised tomography. Seven out of eight patients demonstrated solitary pulmonary nodule in the lung (bronchial carcinoid), and one patient had a mass in the thymus (thymic carcinoid). BIPSS using LVP confirmed the source of ACTH excess correctly in all the patients with ACTH-dependent CS without the loss of specificity.

Open article ↗



antibodies
2022-06-22 | Successful Immunomodulatory Treatment of COVID-19 in a Patient With Severe ACTH-Dependent Cushing’s Syndrome: A Case Report and Review of Literature

Introduction Patients with Cushing’s syndrome (CS) represent a highly sensitive group during corona virus disease 2019 (COVID-19) pandemic. The effect of multiple comorbidities and immune system supression make the clinical picture complicated and treatment challenging. Case report A 70-year-old female was admitted to a covid hospital with a severe form of COVID-19 pneumonia that required oxygen supplementation. Prior to her admission to the hospital she was diagnosed with adrenocorticotropic hormone (ACTH)-dependent CS, and the treatment of hypercortisolism had not been started yet. Since the patient’s condition was quickly deteriorating, and with presumend immmune system supression due to CS, we decided on treatement with intraveonus immunoglobulins (IVIg) that enabled quick onset of immunomodulatory effect. All comorbidities were treated with standard of care. The patient’s condition quickly stabilized with no direct side effects of a given treatment. Conclusion Treatment of COVID-19 in patients with CS faces many challenges due to the complexity of comorbidity effects, immunosupression and potential interactions of available medications both for treatment of COVID-19 and CS. So far, there are no guidelines for treatment of COVID-19 in patients with active CS. It is our opinion that immunomodulating therapies like IVIg might be an effective and safe treatment modality in this particularly fragile group of patients.

Open article ↗



2019-06-05 | A Long-Acting Neutralizing Monoclonal ACTH Antibody Blocks Corticosterone and Adrenal Gene Responses in Neonatal Rats

The control of steroidogenesis in the neonatal adrenal gland is of great clinical interest. We have previously demonstrated that the postnatal day (PD) 2 rat exhibits a large plasma corticosterone response to hypoxia in the absence of an increase in plasma ACTH measured by RIA, whereas the corticosterone response to exogenous ACTH is intact. By PD8, the corticosterone response to hypoxia is clearly ACTH-dependent. We hypothesized that this apparently ACTH-independent response to hypoxia in the newborn rat is due to an increase in a bioactive, nonimmunoassayable form of ACTH. To evaluate this phenomenon, we pretreated neonatal rats with a novel, specific, neutralizing anti-ACTH antibody (ALD1611) (20 mg/kg or 1 mg/kg IP) on the morning of PD1, PD7, and PD14. Twenty-four hours later, we measured hypoxia- or ACTH-stimulated plasma ACTH and corticosterone. For long-term effects, ALD1611 was given on PD1 and pups were studied on PD8 and PD15. Pretreatment with ALD1611 significantly decreased baseline corticosterone and completely blocked the corticosterone response to hypoxia and exogenous ACTH stimulation at all ages. The effect of 1 mg/kg ALD1611 on PD1 had dissipated by PD15. The decrease in corticosterone in ALD1611-treated pups was associated with decreases in baseline and hypoxia- and ACTH-stimulated adrenal Ldlr, Mrap, and Star mRNA expression at all ages. The adrenal response to hypoxia in the newborn rat is ACTH-dependent, suggesting the release of nonimmunoassayable, biologically active forms of ACTH. ALD1611 is useful as a tool to attenuate stress-induced, ACTH-dependent adrenal steroidogenesis in vivo.

Open article ↗



2018-08-23 | Glucocorticoid-induced insulin resistance is related to macrophage visceral adipose tissue infiltration

Insulin resistance is frequently present in patients with glucocorticoid (GC) excess (Cushing’s syndrome) or treated with high doses of GCs. Furthermore, others similarities between metabolic syndrome (visceral obesity, elevated blood glucose levels, dyslipidemia) and Cushing’s syndrome suggest that GCs could play a role in obesity-linked complications. Here we reported that long-term corticosterone (CORT) exposure in mice induced weight gain, dyslipidemia as well as hyperglycaemia and systemic insulin resistance. CORT-treated mice exhibited an increased 11β-Hsd1 expression and corticosterone levels in fat depots but a specific upregulation of glucocorticoid receptor (Gr) and hexose-6-phosphate dehydrogenase only in gonadal adipose tissue, suggesting that GC could act differentially on various fat depots. Despite fat accumulation in all depots, an increased expression of adipogenic (Pparγ, C/ebpα) and lipogenic (Acc, Fas) key genes was restricted to gonadal adipose tissue. Hypertrophied adipocytes observed in both visceral and subcutaneous depots also resulted from reduced lipolytic activity due to CORT treatment. Surprisingly, GC treatment promoted macrophage infiltration (F4/80, Cd68) within all adipose tissues along with predominant M2-like macrophage phenotype, and can directly act on macrophages to induce this phenotype. Moreover, macrophage infiltration preceded mass gain and adipocyte hypertrophy. Of note, specific macrophage depletion in gonadal fat preferentially reduced the M2-like macrophage content, and partially restored insulin sensitivity in mice with GC-induced obesity and insulin resistance. These data provide evidence that GCs act on adipose tissue in a depot-dependent manner and that gonadal adipose macrophages are key effectors of GC-associated insulin resistance.

Open article ↗



2017-02-20 | Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals

Increased cortisol levels in obesity may contribute to the associated metabolic syndrome. In obesity, the activated innate immune system leads to increased interleukin (IL)-1β, which is known to stimulate the release of adrenocorticotropin hormone (ACTH). We hypothesized that in obesity IL-1 antagonism would result in downregulation of the hypothalamo-pituitary-adrenal axis, leading to decreased cortisol levels. In this prospective intervention study, we included 73 patients with obesity (body mass index [BMI] ≥30 kg/m2) and at least one additional feature of the metabolic syndrome. The primary end point was change in morning cortisol from baseline to after the administration of the IL-1 receptor antagonist (anakinra/Kineret®, total dose 3 × 100 mg). Secondary end points were effects on salivary cortisol and ACTH. Median age was 56 years, 50.7% of patients were female, and median BMI was 36.3 kg/m2. Median morning serum cortisol levels (nmol/L) decreased significantly after IL-1 antagonism [from baseline, 452 to 423; absolute difference, −38.7; 95% confidence interval (CI), −64 to −13.4; P = 0.0019]. Similar effects were found for salivary cortisol levels (−2.8; 95% CI, −4.4 to −1.3; P = 0.0007), ACTH levels (−2.2; 95% CI; −4.2 to −0.1; P = 0.038), systolic blood pressure (−5.2, 95% CI, −8.5 to −1.8; P = 0.0006), and heart rate (−2.9; 95% CI, −4.7 to −1.0; P = 0.0029). IL-1 antagonism in obese individuals with features of the metabolic syndrome leads to a decrease in serum cortisol, salivary cortisol, and ACTH levels along with a reduction in systolic blood pressure and heart rate.

Open article ↗



1994-04-01 | The value of inferior petrosal sinus sampling in diagnosis and treatment of Cushing's disease

Summary OBJECTIVE While microsurgical selective adenomectomy is the best method available at present for the treatment of Cushing's disease, its success depends to a large degree on precise preoperative intrapituitary microadenoma localization. This study compares the results of intrapituitary adenoma localization obtained with inferior petrosal sampling, computerized tomography and magnetic resonance imaging with the adenoma localization as found at surgery. DESIGN The results of inferior petrosal sampling for intrapituitary localization of ACTH‐producing pituitary adenomas were compared in a retrospective study with the results of computerized tomography, magnetic resonance imaging, surgical and pathological findings. Special attention was paid to the intersinus ACTH relation. PATIENTS Thirty‐eight patients (33 women and 5 men) of 11‐68 years of age suffering from pituitary‐dependent Cushing's disease were studied. Patients with ectopic ACTH‐secreting tumours and and recurrent pituitary adenomas were excluded. MEASUREMENTS Blood samples were obtained simultaneously from both inferior petrosal sinuses and a peripheral vein before and 5, 10, 15 and 20 minutes after stimulation with 60 /μg/m 2 human corticotrophin‐releasing hormone (hCRH). RESULTS of the adenomas in our series, 42% had a diameter of 3 mm or less. Only 6 of 20 adenomas examined by computerized tomography and 11 of 29 examined by magnetic resonance imaging were identified correctly. Inferior petrosal sinus sampling produced significantly better results, particularly when combined with a stimulation test with hCRH: for 29 of 38 adenomas examined, the location was predicted correctly with these techniques. Analysis of the intersinus adrenocorticotrophin concentration ratio showed that the best right‐central‐left discrimination was obtained with values of 1.3 and 1.4. CONCLUSIONS We conclude that inferior petrosal sinus ACTH sampling after hCRH stimulation is the best method available for the intrapituitary localization of microadenomas causing Cushing's disease provided that the appropriate technique of blood sampling is used meticulously.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

2 orphan drug designations for ACTH-dependent Cushing syndrome, including 1 approved therapy.

2 orphan drug designations for ACTH-dependent Cushing syndrome, including 1 approved therapy.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

Synthetic double-stranded short interfering RNA oligonucleotide directed against proopiomelanocortin

oligonucleotides

EMA
2010-10-01

—

Neurocrine Netherlands B.V.

Corticorelin ovine triflutate [Acthrel]

proteins

FDA
1989-11-24

Approved
1996-05-23

Ferring Laboratories, Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.